UNSPSC 51383403: Zidometacin

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H16N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 446VQG66LC, chemically known as 1h-indole-3-acetic acid, 1-(4-azidobenzoyl)-5-methoxy-2-methyl- but generally known as zidometacin, which bears US NIH Compound Identifier 44179. European Medicines Agency schedules Zidometacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00152MIG.

UNSPSC 51383403 Zidometacin, a Commodity code, does not match the scope of work actually appearing in recent state and local procurement under this code. The three most recent opportunities tagged to this Commodity involve naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products—none of which are zidometacin-specific offerings. The code shows minimal relevant activity; procurement bodies tagging opportunities to it appear to be using the code as a catch-all for pharmaceutical products rather than targeting zidometacin as a discrete product line.

Issuing bodies pursuing pharmaceutical procurement at the state and local level include county health departments (Seminole County, Florida), state HHS commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). Recent opportunities span an RFQ for naloxone and drug deactivation systems (Seminole County IFB60459723LAS, response due July 26, 2023), a Request for Information on direct-to-manufacturer prescription contracting (Texas HHS RFI HHS0017013, posted April 3, 2026), and an RFP for generic multi-source pharmaceuticals and OTC products administered through cooperative purchasing (MMCAP S1070000015802, proposals due March 26, 2026). Activity appears concentrated in Florida and Texas, with Minnesota-based cooperative procurement serving multiple state and local jurisdictions including Oregon. The mismatch between the code's nominal product (zidometacin) and the actual pharmaceutical procurement being pursued suggests limited utility in tracking opportunities under this specific Commodity code.